How many investments has Foresite Capital made?

Foresite Capital has 215 tracked investments, 11 of which have exited via acquisition or IPO, including 5 dated in the last 24 months.

What stage does Foresite Capital invest at?

Foresite Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is Foresite Capital located?

Foresite Capital is headquartered in West Hollywood, US.

Does Foresite Capital lead rounds?

Foresite Capital has led 5 of the 19 rounds where its role is on record.

Who does Foresite Capital co-invest with?

Foresite Capital most often shares deals with RA Capital, OrbiMed, ARCH Venture Partners, among 243 tracked co-investors.

Foresite Capital

Q: What sectors does Foresite Capital focus on?

Foresite Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Venture capital

West Hollywood · Pre-Seed–Late Stage · 62 people tracked

Also known as FORESITE CAPITAL MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Foresite Capital concentrates on the forces transforming healthcare, investing in people, ideas and discoveries that combine technology and biotechnology to personalize care and speed innovation and product development. The firm practices full-lifecycle investing, partnering with companies from incubation through IPO and beyond to have impact regardless of timing. Its team of investment analysts, MD/PhDs and data scientists collaborates closely with portfolio companies, drawing on operational and investment experience and an extensive healthcare network. The firm believes healthcare is undergoing unprecedented innovation fueled by growing understanding of biologic and genetic information, and aims to use its capital and networks to build transformative companies improving the U.S. healthcare system.

Invests inAI & Machine Learning Biotech Digital Health Healthtech Longevity Medical Devices Larkspur United States West Hollywood

Source: firm website, verified Aug 27, 2026.

Stage

Pre-Seed–Late Stage

West Hollywood, CA, US

Instruments

Equity

Founded

2011

Last 12 months

5 investments

AUM

$3.2B

Tracked investments

208

Team · 62 people

from the firm's website & public directories

Jim Tananbaum· Founder & CEO· San Francisco, Californiain 𝕏

Jim Tananbaum is founder and CEO of Foresite Capital Management, a healthcare-focused investment firm based in the San Francisco Bay Area with approximately $4 billion in assets under management as of December 2021. The firm invests in healthcare companies across multiple stages and employs clinical scientists, engineers, analysts, and partners to support portfolio companies.

Jim Tananbaum, MD· Founder & CEO

Vikram Bajaj· Co-founder and CEO of Foresite Labs· Nevadain 𝕏

Vikram Bajaj works at the intersection of large-scale computation, AI, science, and engineering, and is the co-founder and CEO of Foresite Labs. He previously served as Chief Scientific Officer of GRAIL (acquired by Illumina) and was co-founder and Chief Scientific Officer of Verily, an Alphabet company, where he chaired its Scientific Advisory Board. A former academic principal investigator, he is an Adjunct Associate Professor at Stanford University.

Dorothy Margolskee· MD· New Jerseyin

Dorothy Margolskee joined Foresite Capital in 2012, where she has overseen the firm's research and development evaluation group and built an early version of its investment technical review process for analyzing biotechnology portfolios. She previously served as Managing Director in charge of Research at Prospect Ventures, and earlier spent 15 years in drug development at Merck Research Labs, rising to Senior Vice President and contributing to programs including several vaccines and HIV treatments. She holds an M.D. from Johns Hopkins Medical School and a B.A. from Harvard University, and is board certified in Internal Medicine and Pulmonary.

Dorothy Margolskee, MD· Managing Director

Hadi Tabbaa· Managing Director

Hyung Chun· MD, Investment Team· New Haven, Connecticutin

Hyung Chun is a physician scientist who joined Foresite Capital in 2021, where he evaluates investment opportunities in private and public biotech companies. Before Foresite, he was a tenured faculty member at Yale School of Medicine, where he held roles including Co-Director of the Yale Cardiovascular Research Center, and remains an adjunct faculty member. He earned an A.B. in Biochemical Sciences from Harvard College and an M.D. from Johns Hopkins, and completed his residency and cardiovascular fellowship at Stanford.

Hyung Chun, MD· Partner

Michael Rome· Managing Director· Los Angeles, Californiain

Michael Rome, PhD· Managing Director

Richard Lau· Partner· New York, New Yorkin

Richard Lau joined Foresite Capital in 2014, where he works on the investment team handling due diligence and financial modeling of potential investments. He previously served as an equity research analyst covering specialty pharmaceuticals at Wedbush PacGrow Life Sciences and began his career at Pacific Growth Equities, rising from equity research associate to senior analyst covering biotechnology. He holds a B.A. in Molecular and Cell Biology with a biochemistry concentration from UC Berkeley and is a CFA Charterholder.

Richard Lau, CFA· Managing Director

Shannon Bergstedt· Partner· New York, New Yorkin 𝕏

Shannon Bergstedt is a member of the Investment Team at Foresite Capital, where she focuses on life sciences and healthcare technology. She previously spent six years at Verily (formerly Google Life Sciences) as a Business Development Lead, was on the founding team of Evidation Health, and held roles at GE Ventures, Kleiner Perkins, and CardioDx. She holds Bachelor's and Master's degrees from Stanford University and an MBA from Harvard Business School.

Stephen C. Peterson, CFA· Managing Director

Stephen C. Peterson has invested professionally in debt and equity securities since 2004. He is a CFA Charterholder and a member of the CFA Institute and the CFA Society of Colorado. He also serves as a guest lecturer on financial modeling and investment analysis at UC Berkeley's Haas School of Business, the University of Denver's Daniels College of Business, the University of San Francisco, and San Francisco State University.

Stephen Peterson· Partner· Denver, Coloradoin

Stephen Peterson is a Managing Director at Foresite Capital Management, where he identifies and evaluates investment opportunities in healthcare technology and services. He joined the firm in 2011 as its second investment team member and serves on its investment and valuation committees, along with holding board positions at Sollis Health and board observer roles at Thyme Care, Signant Health, and ConnectiveRx. Peterson previously worked as an equity analyst at Palo Alto Investors and Wells Fargo, holds the CFA Charter, and has lectured on investment analysis and financial modeling at multiple universities.

Alisa Mall· Partner· New York, New Yorkin

Dennis Ryan· Managing Director· Californiain

Collin Yang-Wong· Principal· San Francisco, Californiain

Deepak Atri, MD· Principal

Vishal Deshmukh· Member of the Investment Team

Vishal Deshmukh is a member of the investment team at Foresite Capital, where he evaluates investment opportunities in biotech companies. He previously served as Director of Discovery Biology at Kinnate Biopharma, leading early discovery and development of small molecule oncology therapeutics, and as Director of Biology at Biosplice Therapeutics, where he managed programs across oncology, musculoskeletal, and dermatology areas. Earlier he was a Visiting Scientist at Calibr and the Genomics Institute of the Novartis Research Foundation, and he holds a Ph.D. in Biology from The Scripps Research Institute, an M.S. in Biotechnology from UC Irvine, and a B.S. in Pharmaceutical Sciences from the Institute of Chemical Technology, Mumbai.

Vishal Deshmukh, PhD· Principal

Shoman Kasbekar· Principal· San Francisco, Californiain 𝕏

Shoman Kasbekar is an Entrepreneur in Residence at Foresite Labs focused on investing and building in life sciences and healthcare. His career includes experience in venture capital, venture creation, startups, and Fortune 500 companies.

Jorge Reis-Filho, MD, PhD, FRCPath· Venture Partner

Liang Chang, PhD· Venture Partner

Mike Lai, MD· Venture Partner

Travis Young, PhD· Venture Partner

Uplaksh Kumar· Venture Partner· San Francisco Bay Areain

Uplaksh Kumar is a venture partner at Foresite Capital. He previously served as SVP of strategic operations and scale at GRAIL, where he launched the Galleri multi-cancer early detection test, and was the first head of operations at Verily. He has held leadership roles at Life Technologies, BD, LONZA, and Qiagen, and co-founded RoosterBio, a regenerative medicine company focused on research and clinical-grade stem cells.

Alex M. Azar II· Advisor

Alex Azar served as the 24th Secretary of the U.S. Department of Health and Human Services from 2018 to 2021, overseeing a workforce of more than 85,000 and a budget exceeding $1.4 trillion. In that role he oversaw Operation Warp Speed to develop COVID-19 vaccines and therapeutics, and led initiatives on drug pricing, telehealth expansion, health record interoperability, the opioid crisis, and global health security. He has held senior roles in both U.S. government and the private sector, focused on healthcare.

Amelia Stoj· CCO and Assistant General Counsel

Cynthia Carpenter· Executive Associate

Cynthia Carpenter supports the office of the CEO at Foresite Capital. She has over two decades of experience assisting C-level executives, including a prior role supporting Jim Tananbaum at Prospect Venture Partners and serving as an executive assistant to the co-founder at CKS Partners.

Darren Haggerty· Operations Investment Analyst

Darren Haggerty handles the review and reconciliation of the firm's private and public holdings and records associated trading activity. He is an operations and finance professional with more than 20 years of experience in private equity, and previously served as director of operations for Lighthouse Capital. He also has consulting experience.

Deepak Atri· Investment Team· United Statesin 𝕏

Deepak Atri joined Foresite Capital in 2022 as part of the investment team, where he evaluates opportunities in biotech and healthcare companies. A physician-scientist, he earned his MD at Yale as a Howard Hughes Medical Institute research fellow, and completed clinical training in medicine at The Johns Hopkins Hospital and cardiovascular medicine at Brigham & Women's Hospital. He also did a postdoctoral fellowship in molecular and population genetics with Brigham & Women's and The Broad Institute of MIT & Harvard.

Insiya Essani· Senior Associate

Insiya Essani is a member of the investment team at Foresite Capital, where she focuses on therapeutics investment opportunities. She previously worked as a Life Science Consultant at ClearView Healthcare Partners on strategic and due diligence projects for pharma, biotech, and life sciences clients, and held earlier roles at Barclays and Bristol Myers Squibb. She holds a B.A. in Chemistry from Princeton University.

Jacqueline Guttman· Director, IR & Capital Formation

Jacqueline Guttman joined Foresite Capital in 2021 as an Associate Director on the Investor Relations team, where she supports the firm's existing limited partners and manages communications, external events, and content development. She previously spent nearly five years on the investments team at the Carnegie Corporation of New York and worked as an analyst at TD Securities. She holds a Bachelor of Arts in Economics from Barnard College, Columbia University.

Jody Dutton· Senior Executive Administrator

Jody Dutton joined Foresite Capital in 2012 as an early member of the administrative team and provides executive support to the investment team. Before joining the firm, she worked for 10 years as an executive assistant to the President of Food & Beverage at a casino in Northern California, where she handled travel, meetings, and menu planning and design and assisted with two expansions.

Jorge Campos· Compliance Manager

Jorge Campos is a member of Foresite Capital's compliance team, where he helps develop, implement, and maintain the firm's compliance program. He has around eight years of experience in compliance, previously serving as Senior Compliance Associate at CVC Credit Partners and earlier working at the compliance consultancy Cordium.

Kaitlin Montgomery· Executive Assistant

Kara Govi· Executive Assistant

Kara Govi supports the office of the CEO at Foresite Capital. Her background includes senior executive assistant roles across venture capital, startups, and executive search. She holds a degree in Advertising with a minor in Personality and Social Psychology from San Diego State University.

Kelly Ashauer· Executive Assistantin

Kelly Ashauer joined Foresite Capital in 2018, where she provides executive support to the investment team and Investor Relations leadership. Before Foresite, she held roles in the Education and Training office of the Department of Medicine at Memorial Sloan Kettering Cancer Center, most recently supporting the Transitional Year Residency Program. She holds a B.A. in Business Communications from Rockhurst University in Kansas City, MO.

Kevin Kelly· Head of Strategic Trading & ECM Relations

Kevin Kelly joined Foresite Capital in 2018 as a member of the investment team, working on trading that is cost effective and compliant. He has over 20 years of experience in institutional asset management with a focus on SMID Cap trading, operations, and investment process optimization, having previously served as head trader and vice president of operations at RS Investments and beginning his career at Putnam Investments in international trade support. He holds a B.A. from Connecticut College with a concentration in political economies.

Lisa Klyse· Operations Office Manager

Lisa Klyse is an administrative professional with more than 20 years of experience supporting executives across various industries. She joined Foresite Capital in 2019 to support the operations team and the Chief Financial Officer, having previously worked in institutional equity sales supporting sales and trading executives. She holds a B.S. in Hospitality Management from the University of Nevada, Las Vegas.

Lisa Lau· Sr. Manager, Finance & Accounting

Lisa Lau joined Foresite Capital in 2018, where she supports the firm's accounting and operational functions. She previously served as assistant controller at Industrial Growth Partners, a private equity firm, and earlier worked as a tax accountant focused on alternative investments and partnership and corporate entities across the hedge fund, technology, and real estate industries. She holds a BS in Managerial Economics from the University of California, Davis and an MS in Taxation from Golden Gate University.

Liz Canis· Executive Advisor

Liz Canis is an executive advisor at Foresite Capital Management, where she sources opportunities, oversees diligence, monitors portfolio assets, and supports internal incubation efforts. She previously served as vice president of emerging business and partnerships at Elevance Health, ventures lead at healthcare venture firm Savvysherpa, and founder and CEO of The Pivot Group. Earlier she spent eleven years in leadership roles at UnitedHealth Group. She holds a BA from Northwestern University and an MBA from the University of Michigan Ross School of Business.

Luke Bagaason· Manager of Portfolio Valuation· Denver, Coloradoin

Luke Bagaason joined Foresite Capital in 2014 as an analyst and currently serves as Manager of Portfolio Valuation, overseeing monitoring of the firm's privately held investment portfolio. Before Foresite, he operated his own registered investment advisory providing asset management and consulting to investment firms and individuals, and previously worked at JP Morgan Asset Management starting in 2007. He earned the CFA designation in 2013.

Luke Bagaason, CFA· Director, Portfolio Valuation

Madiha Raziuddin· Director, Human Resources

Mark Ponticelli· Executive Advisor

Mark Ponticelli, CFA· Executive Advisor

Mathai Mammen· Advisor

Mathai Mammen has advised Foresite Capital since 2019 and is Chairman and CEO of Parabilis Medicines (formerly FogPharma). He previously served on the Executive Committee of Johnson & Johnson as EVP of J&J Pharmaceuticals R&D and was senior vice president at Merck Research Laboratories, leading research across cardiovascular, metabolic, renal, oncology/immuno-oncology and immunology areas. Earlier he co-founded and led R&D at Theravance, which he built on science from his PhD at Harvard University, and spun out Innoviva and Theravance Biopharma.

Max Lien· Director, IR & Capital Formation

Max Lien joined Foresite Capital in 2023, where he handles investor relations and business development. He previously served as VP of Business & Corporate Development at Hyperscience, an enterprise AI company, where he built the team globally and established partnerships with firms including McKinsey, IBM, and AWS. Earlier in his career, he worked on strategy and corporate/business development teams at Bloomberg and BlackRock, focusing on M&A, partnerships, and growth across financial services, software, and AI.

Melia Granath Panelo· Associate

Nicole McCann· Administrative Assistant

Nicole McCann joined Foresite Capital in 2011, where she supports the administrative team with functions ranging from data entry to process development. She previously held business office roles at Ford on the operations team, working with accounting, human resources, and payroll. She holds an AA with an Accounting concentration from Liberty University and is pursuing a B.S. in Accounting and Business Administration.

Robert Gunderson· Advisor

Robert (Bob) Gunderson is the founding partner and now Chairman Emeritus of Gunderson Dettmer, an international law firm serving emerging growth companies and venture capital and growth equity investors. Over four decades he advised parties in venture financings, IPOs, M&A and fund formations. He co-edited a text on venture capital and public offering negotiation, is a fellow of the American College of Governance Counsel and the American Bar Foundation, and has served as a director of several public companies.

Rowena Dayanghirang· Paralegal

Rowena Dayanghirang supports fund transactions and legal matters at Foresite Capital. Before joining the firm, she spent over five years as a Corporate Paralegal at Gunderson Dettmer, LLP, handling corporate and transactional work for private companies across various industries. She previously worked as a Corporate Paralegal Assistant at Perkins Coie, LLP for two years.

Susan Gatrill· Manager, Fund Accounting

Susan Gatrill joined Foresite Capital's accounting team in 2015, where she handles review, reconciliation, and analysis of fund financial activity along with quarterly reporting. She has close to 20 years of experience in venture capital accounting, including 13 years as a fund accountant and later senior accountant at Lighthouse Capital Partners, a venture debt firm, where she managed daily operations and monthly and quarterly close for multiple investment funds.

The Honorable Alex M. Azar II· Advisor

Tiffany Bond· Sr. Accounting & Administration Associate

Tiffany Bond handles day-to-day accounting for Foresite Capital's entities, including accounts payable and receivable, capital call and cash distribution processing, and daily cash management. She joined the firm in November 2014. Before that, she was the office and technology manager at Kreuzberger|Associates, a finance and accounting recruiting firm in the San Francisco Bay Area.

Vikram Bajaj, PhD· Advisor

Cindy Xiong· Investor· New York, New Yorkin

Jonathan Robbins· Investor· Boston, Massachusettsin

Marguerite Davis· Delaware

Matt Buten· Managing Director· New York, New Yorkin

Matthew Buten is Chief Financial Officer at Biohaven Pharmaceuticals. He has venture capital and private equity experience and holds a degree from the Wharton School at the University of Pennsylvania.

Founder mafia

3 people who came through Foresite Capital went on to found or lead other companies.

Vikram BajajCo-founder and CEO of Foresite LabsFounded Verily +1 Jacob RobinsonVenture FellowFounded VO Health +1 Damien SoghoianDirectorFounded Seranova Bio

What they invest in

from 142 of 208 portfolio companies

Biotech ×117Healthtech ×82Medical Devices ×39Digital Health ×24AI & Machine Learning ×20Deep Tech ×11Enterprise Software ×4Hardware ×4

HQs:United States×97United Kingdom×3Denmark×1

Who they back

founder profiles across 62 portfolio companies

55%

solo founders

34 of 62 mapped founding teams

57%

repeat founders

of 21 founders with career history

~2 yrs

old at investment

median across 27 dated deals

Founding team size:solo founder×342 founders×193 founders×54+ founders×4

Where their founders studiedfrom 21 founders with education data

Harvard University ×3University of California, Berkeley ×3The Hebrew University of Jerusalem ×2

Where their founders worked beforefrom 21 founders with career history

Stanford University ×3Flatiron Health ×2University of California, Berkeley ×2

11 founders hold a PhD · 3 hold an MBA (of 21 with degree data)

Investments · 208 tracked

founders shown can be your intro path

By year:2026 · 3 2025 · 5 2024 · 9 2022 · 2 2021 · 6 2020 · 1 2019 · 2 2018 · 5 2017 · 1 2016 · 5 2015 · 7 2014 · 349 dated

Alumisalumis.com in 𝕏NASDAQ: ALMSJul 2024

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)

Board seatJames Tananbaum· per SEC Form D

Co-investorsNextech Invest OrbiMed Samsara BioCapital SR One Capital Management venBio Partners Westlake Village BioPartners +1 more

Eikon Therapeutics inNASDAQ: EIKNFeb 2025

BiotechHayward, US

Roger M. Perlmutter(Executive Officer, Director)

BoardJoshua Wolfe(Director)inDror Berman(Director)Leon Chen(Director)Adam Goulburn(Director)in

Board seatJames Tananbaum· per SEC Form D

Co-investorsLux Capital Dimension Capital

Fulcrum Therapeutics inNASDAQ: FULCAug 2018

BiotechCambridge, US

Robert Gould(Executive Officer, Director)

BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsThird Rock Ventures

10x GenomicsNASDAQ: TXG

Next-generation genetic sequencing using microfluidics for sequencing and molecular diagnostics

Co-investorsFoothill Ventures Khosla Ventures Paladin Capital Group Venrock

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners F-Prime Capital RA Capital Sofinnova Ventures Sofinnova Venture Partners +1 more

Adaptimmune Therapeutics PlcOTC: ADAPYSep 2014

BiotechAbingdon, Oxfordshire

David Mott(Director)Ali Behbahani(Director)Peter Thompson(Director)Elliott Sigal(Director)Dr. Jonathan Knowles(Chairman)James Noble(Chief Executive Officer)

Adaptive Biotechnologiesadaptivebiotech.com in 𝕏NASDAQ: ADPT

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Executive Officer, Director)Harlan Robins(Executive Officer)inKathleen Determann(Executive Officer)Dean Schorno(Executive Officer)Chris Carlson(Executive Officer)

BoardArnold Levine(Director)

Co-investorsDecheng Capital FMG Capital Khosla Ventures OrbiMed

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)

BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)Erez Chimovits(Director)in

Co-investorsOrbiMed Pontifax Venture Capital Quan Capital aMoon Novartis Venture Fund

Alectoralector.com in 𝕏NASDAQ: ALECSep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsMission Bay Capital Mission Biocapital MRL Ventures Fund SV Health Investors Polaris Partners

Allogene Therapeuticsallogene.com in 𝕏NASDAQ: ALLOApr 2018

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)

BoardOWEN WITTE(Director)

Co-investorsAvoro Capital Advisors TPG Vida Ventures

Alx Oncologyalxoncology.com in 𝕏NASDAQ: ALXO

ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.

BiotechHealthtech

Co-investorsage1 Lightstone Ventures venBio Partners

Arbutus Biopharma Corporationarbutusbio.com inNASDAQ: ABUSDec 2016

Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.

BiotechHealthtechWarminster, US

William H. Collier(President and Chief Executive Officer)Gaston Picchio(Chief Development Officer)Michael J. McElhaugh(Chief Business Officer)David C. Hastings(Chief Financial Officer)Michael J. Sofia(Chief Scientific Officer)Elizabeth Howard(Executive Officer)

Aura Biosciencesaurabiosciences.com in 𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life Sciences Chiesi Ventures Droia Ventures Jazzya Investments Medicxi Myelin VC +4 more

Beam Therapeuticsbeamtx.com in 𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder and Inventor)J. Keith Joung(Founder and Inventor)Feng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture Partners Dreamers VC Eight Roads Ventures F-Prime Capital GV (Google Ventures)HongShan Capital Group +1 more

Bicara Therapeuticsbicara.com in 𝕏NASDAQ: BCAX

Co-investorsAisling Capital Eight Roads Ventures F-Prime Capital Premji Invest RA Capital Red Tree Venture+1 more

Casi Pharmaceuticalscasipharmaceuticals.com inOTC: CASIF

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells.

BiotechHealthtechBeijing

Chunhua Wang(Chief Operating Officer)Wei Gao(General Counsel)Hai Huang(Global Chief Commercial Officer)Alexander A. Zukiwski(Chief Medical Officer)Wei (Larry) Zhang(President)Wei-Wu He(Chief Executive Officer, Chairman of the Board of Directors)

Celldex Therapeutics, Inc.celldex.com in 𝕏NASDAQ: CLDXNov 2016

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.

BiotechHealthtechHampton, US

Anthony S. Marucci(Executive Officer, Director)Avery W. Catlin(Executive Officer)Timothy M. Shannon, M. D.(Director)

BoardRichard van den Broek(Director)Herbert J. Conrad(Director)Karen Shoos(Director)

CG Oncologycgoncology.com in 𝕏NASDAQ: CGON

CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.

BiotechHealthtech

Co-investorsDecheng Capital Longitude Capital Palm Drive Capital RA Capital TCG Crossover ACORN BIOVENTURES +2 more

Compass Therapeuticscompasstherapeutics.com in 𝕏NASDAQ: CMPX

Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.

BiotechHealthtechCambridge, US

Co-investorsBioBrit F-Prime Capital OrbiMed venBio Partners Vivo Capital

Crinetics Pharmaceuticals, Inc.NASDAQ: CRNX

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen F. Betz(Executive Officer)YunFei Zhu(Executive Officer)

BoardMahendra Shah(Director)Steve Kaldor(Director)Mason Freeman(Director)

Co-investorsVivo Capital

Cullinan Therapeuticscullinantherapeutics.com in 𝕏NASDAQ: CGEM

Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers.

BiotechHealthtech

Co-investorsNextech Invest Biotechnology Value Fund OrbiMed

Cytokineticscytokinetics.com in 𝕏NASDAQ: CYTK

Cytokinetics is a biopharmaceutical company focused on muscle biology, developing small molecule muscle activators and inhibitors to treat diseases involving compromised muscle function, including heart failure, hypertrophic cardiomyopathy, and neuromuscular diseases.

BiotechHealthtech

Denali Therapeuticsdenalitherapeutics.comNASDAQ: DNLIFeb 2024

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Director)Ryan Watts(Executive Officer, Director)Alexander O. Schuth(Executive Officer)Carole Ho(Executive Officer)Steve E. Krognes(Director)

BoardDavid P. Schenkein(Director)in

Co-investorsARCH Venture Partners EcoR1 Capital F-Prime Capital GV (Google Ventures)

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Frazier Life Sciences OrbiMed

Edgewise TherapeuticsNASDAQ: EWTX

Boulder, US

Kevin Koch(Executive Officer, Director)Alan Russell(Director)Kenneth Harrison(Director)

BoardPeter Thompson(Director)Jonathan Root(Director)

GH Researchghres.comNASDAQ: GHRS

GH Research is a clinical-stage pharmaceutical company developing mebufotenin (5-MeO-DMT) based therapies for psychiatric and neurological disorders.

BiotechDigital HealthMental Health

Co-investorsRA Capital

GRAILgrail.com in 𝕏NASDAQ: GRAL

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)

Co-investorsAmino Capital ARCH Venture Partners Bezos Expeditions Bluebird Ventures Decheng Capital Dentsu Ventures +8 more

Hinge Healthhingehealth.com in 𝕏NYSE: HNGE

Hinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions.

Digital HealthHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Gabriel Mecklenburg(Executive Officer, Director)inDaniel Perez(Executive Officer, Director)

Co-investors11.2 Capital Alkeon Innovation Bessemer Venture Partners Cannage Capital Coatue Management Duke Capital Partners +8 more

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will LewisinGeoffrey Allanin

Co-investorsBessemer Venture Partners F-Prime Capital OrbiMed Prospect Venture Partners NVIDIA

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)

Co-investorsage1 Atlas Venture Avoro Capital Advisors EcoR1 Capital

Invivydinvivyd.com in 𝕏NASDAQ: IVVD

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life Sciences MRL Ventures Fund Premji Invest

Keros TherapeuticsNASDAQ: KROS

BiotechLexington, US

Jasbir S. Seehra(Executive Officer, Director)

BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)

Co-investorsArkin Capital OrbiMed

Kura Oncologykuraoncology.com inNASDAQ: KURA

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TROY WILSON(Executive Officer, Director)PINGDA REN(Executive Officer)YI LIU(Executive Officer)Troy Wilson(Founder)inHEIDI HENSON(Executive Officer)ANNETTE NORTH(Executive Officer)

Co-investorsARCH Venture Partners Avoro Capital Advisors EcoR1 Capital Nextech Invest OUP (Osage University Partners)

Madrigal PharmaceuticalsNASDAQ: MDGLApr 2016

BiotechFort Washington, US

Rebecca Taub(Executive Officer, Director)

BoardFred Craves(Director)Lionel Carnot(Director)

Maze Therapeuticsmazetx.com in 𝕏NASDAQ: MAZE

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Frazier Life Sciences GV (Google Ventures)Janus Henderson Investors Venrock Healthcare Capital Partners

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in

Co-investorsBain Capital Life Sciences Cheyenne Ventures Claremont Creek Ventures Harmony Partners Lightspeed Venture Partners RA Capital +1 more

Olema PharmaceuticalsNASDAQ: OLMA

BiotechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)David C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)Shane Kovacs(Executive Officer)

Omeros Corp.omeros.comNASDAQ: OMER

Omeros is a biopharmaceutical company developing small-molecule and protein therapeutics aimed at diseases with significant unmet medical needs.

BiotechHealthtech

Co-investorsSPRINGROCK VENTURES

Parabilis Medicinesparabilismed.com inNASDAQ: PBLS

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)

Co-investorsARCH Venture Partners Catalio Capital Management, LP Frazier Life Sciences General Catalyst Nextech Invest RA Capital +5 more

Quince TherapeuticsNASDAQ: QNCX

BiotechSouth San Francisco, US

Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)Brendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)Kristen Gafric(Executive Officer)

Co-investorsSofinnova Partners

Relay Therapeutics inNASDAQ: RLAYJan 2024

Improving patients' lives by accelerating development and commercialization of medicines that matter.

BiotechCambridge, US

Sanjiv K. Patel(Executive Officer, Director)Donald A. Bergstrom(Executive Officer)Thomas Catinazzo(Executive Officer)Peter Rahmer(Executive Officer)Sekar Kathiresan(Director)Douglas S. Ingram(Director)

Co-investorsCommonweal Ventures Curie.Bio

Replimune GroupNASDAQ: REPL

Co-investorsBain Capital Life Sciences

Revolution MedicinesNASDAQ: RVMD

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Co-investorsBain Capital Life Sciences Nextech Invest Third Rock Ventures

Rxsightrxsight.com in 𝕏NASDAQ: RXST

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Joseph Devivo(Director)James N. Adler(Director)Robert H. Grubbs(Director)Werner F. Wolfen(Director)D. Verne Sharma(Executive Officer, Director)Javier Perez-Sala(Director)

Co-investorsFlying L Partners H.I.G. Capital H.I.G. HealthBridge Partners Longitude Capital RA Capital Visionary Ventures +1 more

Scynexisscynexis.com in 𝕏NASDAQ: SCYX

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)Horace D. Nalle(Director)Pamela J. Kirby(Director)Laurent Arthaud(Director)Mounia Chaoui(Director)Patrick Langlois(Director)

Co-investorsDecheng Capital

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)

BoardJames I. Healy(Director)

Co-investorsARCH Venture Partners HAWKTAIL PureTech Health Sofinnova Ventures

Silence Therapeuticssilence-therapeutics.comNASDAQ: SLNFeb 2021

BiotechLondon

James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)

Co-investorsMC Healthcare Ventures Nextech Invest Vivo Capital

Solid Biosciencessolidbio.com in 𝕏NASDAQ: SLDB

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Stephen DiPalma(Executive Officer)Alexander (Bo) Cumbo(Executive Officer, Director)Carl Morris(Executive Officer)Martin Freed(Director)Paul Herizch(Executive Officer)Robert Huffines(Director)

Co-investorsBain Capital Life Sciences RA Capital

Syndax Pharmaceuticals inNASDAQ: SNDX

BiotechWaltham, US

Dennis Podlesak(Director)Ivor Royston(Director)John Pallies(Executive Officer)Luke Evnin, Ph.D.(Director)George W Sledge, Jr. M.D.(Director)Fabrice Egros, Ph.D.(Director)

Co-investorsPappas Capital Sofinnova Ventures venBio Partners

Tango Therapeuticstangotx.comNASDAQ: TNGX

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Co-investorsNextech Invest NSG Ventures Third Rock Ventures

Vaxcytevaxcyte.comNASDAQ: PCVX

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in

Co-investorsBioRock Ventures CTI Life Sciences Fund L.P.Frazier Life Sciences Longitude Capital RA Capital

Verastemverastem.com in 𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergAMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)BRIAN STUGLIK(Executive Officer, Director)

Co-investorsBessemer Venture Partners Cardinal Partners Lightstone Ventures Longwood Fund Oberland Capital OrbiMed

Wave Life Scienceswavelifesciences.com in 𝕏NASDAQ: WVE

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore

Co-investorsRA Capital

Xenon Pharmaceuticals IncNASDAQ: XENE

Remix Therapeuticsremixtx.com in 𝕏Jan 2024✓ verified

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)

Board seatMichael Rome· per SEC Form D

Co-investorsAtlas Venture The Column Group ARCH Venture Partners Decheng Capital

Bit Biobit.bio in 𝕏✓ verified

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

Dr Mark Kotter(Founder)Przemek Obloj(CEO)Emma Pepperellin

Co-investorsBlueYard Capital ARCH Venture Partners Dynamk Capital Good AI Capital HAWKTAIL Metaplanet +2 more

Cerevancecerevance.com in 𝕏✓ verified

Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.

BiotechDeep TechHealthtech

Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)

Co-investorsGV (Google Ventures)Dementia Discovery Fund SV Life Sciences Dementia Discovery Lightstone Ventures SV Health Investors +2 more

Curisiumhealthverity.com in 𝕏✓ verified

HealthVerity operates a healthcare and consumer data ecosystem that enables HIPAA-compliant synchronization and exchange of real-world data across pharma, payers, and government agencies.

Data & InfrastructureEnterprise SoftwareHealthtechPhiladelphia, US

Andrew Kress(Co-Founder and CEO)inAndrew Goldberg(Co-Founder and COO)

BoardMichael Greeley(Director)inRachel Winokur(Director)

Co-investorsFlare Capital Partners Greycroft New Enterprise Associates (NEA)

Engrail Therapeuticsengrail.com in✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsLongwood Fund Norwest Venture Partners RiverVest Venture Partners Ysios Capital abrdn plc Eight Roads Ventures +4 more

Pleno Inc.plenoinc.com✓ verified

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsMedical Excellence Capital Deerfield Management Company

Allergen ResearchJan 2015SEC filingmedium confidence

HealthtechSan Mateo, US

Victor Colunga(Executive Officer)Stephen G. Dilly, Jr.(Executive Officer, Director)

BoardJoonkyoo (Anthony) Yun(Director)Stacey D. Seltzer(Director)Patrick Enright(Director)

Board seatJames Tananbaum· per SEC Form D · $80M raise · filed Mar 2015

Co-investorsQiming Healthcare

Fl2021-001Feb 2021SEC filinghigh confidence

HealthtechSan Francisco, US

June Lee(Executive Officer, Director)

BoardJames Tananbaum(Director)

Board seatMichael RomeVikram Bajaj· per SEC Form D · $60M raise · filed Mar 2021

Co-investorsSamsara BioCapital

Interline Therapeutics, Inc.Nov 2021SEC filinghigh confidence

HealthtechSouth San Francisco, US

Zachary Sweeney(Executive Officer, Director)

Board seatJames TananbaumVikram Bajaj· per SEC Form D · $50M raise · filed Nov 2021

Kinnate Biopharmakinnate.comDec 2019

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)

Board seatMichael Rome· per SEC Form D

Co-investorsNextech Invest Janus Henderson Investors RA Capital Venrock Healthcare Capital Partners Viking Global Investors

Pardes Biosciencespardesbio.com inFeb 2021

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechSan Francisco, US

Uri Lopatin(Founder/CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)Elizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)

BoardJ. Jay Lobell(Director)

Board seatJames B. Tananbaum· per SEC Form D

Co-investorsY Combinator Khosla Ventures

Spear BioJul 2024

BiotechWoburn, US

Feng Xuan(Executive Officer, Director)Peng Yin(Director)John Wu(Executive Officer)Wen Chan(Director)Michael Natan(Executive Officer, Director)

BoardDavid Singer(Director)

Board seatVikram Bajaj· per SEC Form D

Tarsa Therapeuticstarsatherapeutics.comFeb 2016SEC filingmedium confidence

Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.

BiotechPhiladelphia, US

David Brand(Executive Officer, Director)Gregory Lumpkin(Executive Officer)Ashleigh Palmer(Director)Matthew Rieke(Director)

BoardRichard Kollender(Director)Martin Edwards(Director)

Board seatJames Tananbaum· per SEC Form D · $2M raise · filed Feb 2016

Co-investorsMVM Life Science Partners

Theseus Pharmaceuticalstheseusrx.comJun 2018

BiotechCambridge, US

William C. Shakespeare(Director)

BoardIain Dukes(Executive Officer, Director)inCarl Gordon(Director)in

Board seatMichael Rome· per SEC Form D

Co-investorsLongitude Capital Nextech Invest OrbiMed

89 Bio, Inc. (Alumni)

Abcuroabcuro.comAug 2026

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life Sciences New Enterprise Associates (NEA)RA Capital Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures +8 more

Abdera Therapeutics

Acceleronacceleronpharma.com in 𝕏

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)KEVIN F. MCLAUGHLIN(Executive Officer)RICHARD POPS(Director)EDWIN M. KANIA(Director)CARL L. GORDON(Director)

Co-investorsBessemer Venture Partners Lightstone Ventures Lowercarbon Capital Sofinnova Ventures Venrock Collaborative Fund

Acceleron Pharma

Aduro BiotechDec 2014

BiotechBerkeley, US

Thomas Dubensky(Executive Officer)Dirk G. Brockstedt(Executive Officer)Stephen Isaacs(Executive Officer, Director)Jennifer Lew(Executive Officer)Gregory W. Schafer(Executive Officer)Gregory Schafer(Executive Officer)

Co-investorsFranklin Templeton OrbiMed

Aerie Pharmaceuticals, Inc. (Alumni)

Aeriepharmaaeriepharma.com in

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

DAVID GRYSKA(Director)VICENTE ANIDO(Executive Officer, Director)MURRAY GOLDBERG(Director)ANAND MEHRA(Director)BRIAN LEVY(Executive Officer)GERALD CAGLE(Director)

Co-investorsAlta Partners Avoro Capital Advisors OUP (Osage University Partners)Sofinnova Ventures

Aetion

Co-investorsB Capital Group Flare Capital Partners

Affinivaxaffinivax.com in 𝕏

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)Kamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBain Capital Life Sciences EcoR1 Capital

Aimmune Therapeutics

Akeroakerotx.com in 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Frazier Life Sciences Scion Life Sciences The Innovation Space venBio Partners Versant Ventures

Ambit Biosciences Corporation

Apollo Health Venturesapollo.vc in 𝕏Jan 2026

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN Capital CoastCap FJ Labs KfW Capital TruVenturo GmbH CTI Life Sciences Fund L.P.+3 more

Arcus Biosciencesarcusbio.com in 𝕏

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling Capital Decheng Capital Droia Ventures EcoR1 Capital SLVC Sofinnova Ventures +2 more

Ardelyxardelyx.com 𝕏

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.

BiotechFremont, US

Michael Raab(Executive Officer, Director)Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)David Rosenbaum(Executive Officer)Jeremy Caldwell(Executive Officer)Mike Raabin

Co-investorsHEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)

Arriventarrivent.com inDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LP General Catalyst HongShan Capital Group LAV Lilly Asia Ventures OrbiMed +2 more

Ascendis Pharmaascendispharma.com in 𝕏Nov 2014

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)James Healy(Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Rafa?le Tordjman(Director)Martin Olin(Director)

Co-investorsVivo Capital Aisling Capital Avoro Capital Advisors RA Capital Sofinnova Ventures

Audentes

Co-investors5AM Ventures

Avanir Pharmaceuticals

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed Quan Capital +3 more

AveXis

New gene therapy treatments for people with serious, rare diseases.

Co-investorsPBM Capital RA Capital Sofinnova Ventures

Bellicum Pharmaceuticals

Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.

BiotechHouston, US

Ken Moseley(Executive Officer)Thomas J. Farrell(Executive Officer, Director)James F. Brown(Director)Annemarie Moseley(Executive Officer)Joseph Senesac(Executive Officer)Frank McGuyer(Director)

Co-investorsRA Capital Rapha Capital Management, LLC

Biodelivery Sciences International Copy

Biohaven Pharmaceutical

Blueprint Medicinesblueprintmedicines.com in 𝕏

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Daniel Lynch(Director)Nick Lydon(Director)David Schenkein(Director)Christoph S. Lengauer(Executive Officer)Christine Bellon(Executive Officer)Kyle Kuvalanka(Executive Officer)

Co-investorsF-Prime Capital Nextech Invest RA Capital

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsOrbiMed Samsara BioCapital TCG Crossover Third Rock Ventures venBio Partners Vida Ventures

Centessa Pharmaceuticalscentessa.com

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsAdvent Life Sciences EcoR1 Capital Medicxi Oberland Capital Scion Life Sciences Vida Ventures +1 more

Chimagen Biosciences

Color Healthcolor.com in 𝕏

Color Health operates a nationwide virtual cancer clinic delivering oncologist-led care, screening, and treatment management for employer, union, health plan, and public sector populations.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Othman Laraki(CEO)

Co-investors8VC Comcast Ventures CRV (Charles River Ventures)Dria Ventures Homebrew Kindred Ventures +7 more

ConnectiveRxconnectiverx.com in

ConnectiveRx provides hub services, patient support, and patient affordability programs that help pharmaceutical manufacturers, healthcare providers, and patients access and stay on prescribed therapies.

Digital HealthHealthtechSaaS

Co-investorsGenstar

Copy

Corvuspharmacorvuspharma.com inSep 2015

Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer.

BiotechHealthtechBurlingame, US

Richard A. Miller(Executive Officer, Director)Leiv Lea(Executive Officer)Terry G. Gould(Director)

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Director)

Co-investorsAvoro Capital Advisors OrbiMed

Crossover Health, Inc. (Alumni)

Cue Healthcuehealth.com

Clint Sever(Founder)in

Co-investorsDarwin Capital Decheng Capital Dentsu Ventures Prime Partners ACME Capital CAVU Consumer Partners+1 more

Cymabaycymabay.com in 𝕏Aug 2015

Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.

BiotechHealthtechNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)

Co-investorsAvoro Capital Advisors Bay City Capital VantagePoint Capital Partners

Delfi Diagnosticsdelfidiagnostics.com in

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Executive Officer, Director, Promoter)Peter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)

BoardRishi Gupta(Director)in

Co-investorsAV8 Ventures Illumina Ventures Menlo Ventures Open Field Capital OrbiMed OUP (Osage University Partners)+3 more

Dermiradermira.com

HealthtechMenlo Park, US

THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)ANDREW GUGGENHIME(Executive Officer)LUIS PENA(Executive Officer)CHRISTOPHER GRIFFITH(Executive Officer)David E. Cohen(Director)

Co-investorsAisling Capital Bay City Capital Canaan Partners New Enterprise Associates (NEA)Fidelity Investments Qiming Healthcare +1 more

Detect, Inc.

Dnanexusdnanexus.com in 𝕏Apr 2015

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.

AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US

Richard Daly(Executive Officer, Director)George Asimenos, PhD(Chief Product Officer)inMichael Goldberg(Director)Nathaniel Goldhaber(Director)Andreas Sundquist(Executive Officer, Director)Geoff Duyk(Director)

Co-investorsClaremont Creek Ventures GV (Google Ventures)K9 Ventures Uncork Capital Wireframe Ventures

Dyax Corp

Eidos TherapeuticsMar 2018

BiotechSan Francisco, US

NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)

Co-investorsRA Capital

Elementelement.com in

Element is a global provider of lab-based Testing, Inspection and Certification (TIC) services, including destructive and non-destructive material testing, product qualification testing, and certification of products and management systems.

Advanced ManufacturingEnterprise SoftwareNew Materials

Co-investors3i Group Metaplanet Protocol Labs T. Rowe Price Venrock

Element Bioscienceselementbiosciences.com in 𝕏

Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.

BiotechDeep TechHardwareMedical Devices

Co-investorsDraper Associates Fusion RA Capital TSVC Venrock

Engene Holdings Inc

Epizyme, Inc. (Alumni)

Everly Healtheverlywell.com in 𝕏

Everlywell offers at-home lab testing kits and virtual healthcare services across multiple wellness categories including daily health screening, digestive analysis, sexual health testing, and hormone monitoring.

Digital HealthHealthtechWellness & Fitness

Julia Cheek(Founder & CEO)

Co-investorsAnsa Capital Halogen Ventures Management Company Llc Next Coast Ventures NextGen Venture Partners Portfolia The Chernin Group (TCG Crypto)+3 more

Everly Healtheverlyhealth.com in 𝕏

Everlyhealth operates an at-home laboratory testing platform that enables consumers to monitor their health through biomarker analysis across multiple categories including daily health, digestive health, sexual health, and hormone health, with optional virtual care consultations.

ConsumerDigital HealthHealthtech

Co-investorsBreyer Capital Cerity Partners Ventures Halogen Ventures Management Company Llc Lux Capital Next Coast Ventures NextGen Venture Partners +2 more

Evonetix

Fabric Genomicsfabricgenomics.com in 𝕏

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices

Martin Reese(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)

Co-investorsArtis Ventures Mighty Capital Casdin Capital

Fibrogen

Folxfolxhealth.com in 𝕏

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)Liana M Guzman Weis(Executive Officer, Director)

BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in

Co-investors7wire Ventures Bessemer Venture Partners Corewell Health Ventures Define Ventures Habitat Partners Seae Ventures +2 more

Foresight Diagnostics

Galileo

Generation Biogenerationbio.com

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas Venture F-Prime Capital Invus

Genomics Plcgenomics.com in 𝕏

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.

AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB

Peter Donnelly

Co-investorsF-Prime Capital

Genomics PLC

Healthcare North America Growth Stageaetion.com in

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)

Co-investorsB Capital Group B4 Capital Blue Lion Global Flare Capital Partners LG Technology Ventures McKesson Ventures+6 more

HealthVerity

Co-investorsFlare Capital Partners

Hims & Hershims.com

US direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.

Jack Abraham(Co-founder)in

Co-investors7GC & Co 8VC A-Rod Corp Atomic Brentwood Associates CAVU Consumer Partners +16 more

identifeye HEALTHidentifeye.health in

identifeye health develops an automated retinal imaging platform that captures high-quality fundus images at the point-of-care and integrates into clinical workflows.

AI & Machine LearningDigital HealthMedical Devices

Ikena Oncology, Inc.

BiotechBoston, US

Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)

BoardOtello Stampacchia(Director)in

Co-investorsAtlas Venture Biotechnology Value Fund Omega Funds OrbiMed RTW Investments L.P.

ImageneBio, Inc. (Alumni)

Immpact Bio Usa

Immunomedics, Inc. (Alumni)

Indomo

Inscriptainscripta.com

BiotechBoulder, US

Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)

BoardRoger Wyse(Director)inBryan Roberts(Director)

Co-investorsiGlobe Partners Korys Oak HC/FT OMX Ventures Paladin Capital Group Spruce Capital Partners +3 more

Insitroinsitro.com in 𝕏Mar 2020

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)

BoardRobert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen Horowitz ARCH Venture Partners GV (Google Ventures)HOF Capital SoftBank Vision Fund Bezos Expeditions +5 more

Intarcia TherapeuticsDec 2016

Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.

BiotechBoston, US

James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)

Co-investorsBay City Capital Cycad Group LLC NXT Ventures

Ivantis

Co-investorsRA Capital

Jade Biosciencesjadebiosciences.com in

Jade Biosciences is a clinical-stage biotech company developing antibody-based therapies for autoimmune diseases, with a lead candidate (JADE101) targeting the cytokine APRIL for the treatment of immunoglobulin A nephropathy (IgAN).

BiotechHealthtech

Co-investorsFrazier Life Sciences

Karyopharmkaryopharm.com in 𝕏Dec 2022

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

Stuart Poulton(Executive Officer)Michael Mano(Executive Officer)Reshma Rangwala(Executive Officer)Richard Paulson(Executive Officer, Director)Stephen Mitchener(Executive Officer)Michael Mason(Executive Officer)

Co-investorsAvoro Capital Advisors HEALTHCARE ROYALTY PARTNERS

Khartis Therapeuticskhartis.com in

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsNextech Invest Alexandria Lilly Asia Ventures Longwood Fund

Kinnate Biopharma (Alumni)

Kira Pharmaceuticalskirapharma.com in

Kira Pharmaceuticals develops therapies targeting the complement system for patients with complement-mediated autoimmune and inflammatory diseases across areas including hematology, nephrology, neurology, dermatology and ophthalmology.

BiotechHealthtech

Wenru Song(Founder)

Co-investorsQuan Capital Vivo Capital Ikarian Capital

Kriya Therapeuticskriyatherapeutics.com in 𝕏Jun 2021 · $1.2B

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

Shankar Ramaswamy(Co-Founder, Chairman & CEO)Roger Jeffs(Co-Founder & Vice Chairman)Fraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)Shankar Ramaswamy, M.D.(Founder)inMichele Stone(Chief Scientific Officer)Katherine Eade(Chief Legal Officer)

Co-investorsPatient Square Capital Premji Invest Amplo Ventures Bluebird Ventures JDRF T1D Fund Narya Capital +2 more

Latigo Biolatigobio.comJan 2025

Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.

BiotechHealthtechThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)

BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)

Co-investorsAccess Biotechnology Kern Capital, LLC Sanofi Ventures 5AM Ventures Westlake Village BioPartners

Lucira Healthlucirahealth.com in

Lucira Health manufactures portable diagnostic devices that connect to smartphones to test bodily fluids for infectious diseases, enabling rapid results outside of clinical settings.

BiotechHealthtechMedical DevicesEmeryville, US

Debkishore Mitra(Founder)inJohn R. Waldeisen(Director)

BoardErik T. Engelson(Executive Officer, Director)Justin Butler(Director)Tuff Yen(Director)Steve Tablak(Director)

Co-investors11.2 Capital ShangBay Capital LLC Y Combinator OS Fund

Lundbeck Seattle Biopharmaceuticals Inc

Lyelllyell.com in

Lyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors.

BiotechHealthtech

Co-investorsARCH Venture Partners venBio Partners 8VC Axial VC

Mammoth Biosciencesmammoth.bio in 𝕏

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

BiotechDeep TechMedical DevicesBrisbane, US

Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)

BoardUrshit Parikh(Director)

Co-investors8VC Berkeley Frontier CALIFORNIA INNOVATION Decheng Capital Mayfield Fund Mission Bay Capital +9 more

Mirviemirvie.com inJul 2025

Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.

BiotechFemTechHealthtechSouth San Francisco, US

Maneesh Jain(Executive Officer, Director, Promoter)inStephen Quake(Director)

BoardLisa Iverson(Director)Ursheet Parikh(Director)inMin Cui(Director)inSamir Kaul(Director)in

Co-investorsDecheng Capital Mayfield Fund Portfolia General Catalyst Khosla Ventures

Modal Therapeutics Inc.

Momenta Pharmaceuticals, Inc. (Alumni)

MyokardiaApr 2015

BiotechSouth San Francisco, US

Tassos Anastasios Gianakakos(Executive Officer, Director)

BoardKevin Starr(Director)inCharles Homcy(Director)Mark Perry(Director)Katherine Bowdish(Director)

Co-investorsKhosla Ventures Third Rock Ventures

Myomemyome.com in 𝕏

MyOme uses whole genome sequencing and bioinformatics to analyze a single patient sample and produce clinically actionable reports, offering both proactive health tests (such as polygenic risk scores and medication response) and diagnostic tests for rare disease.

BiotechDigital HealthHealthtech

Co-investorsHOF Capital Samsung Next

Mythic Therapeutics

Nanostring

Nested Therapeuticsnestedtx.com in 𝕏

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)Darrin Miles(Chief Executive Officer)Philip Komarnitsky(Chief Medical Officer)Tanja Weber(Chief Business Officer)

Co-investorsVersant Ventures Sixty Degree Capital Cowen Healthcare Investments Goldman Sachs

Neurodermneuroderm.com in

Ngm Biopharmaceuticals

BiotechSouth San Francisco, US

Jin-Long Chen(Executive Officer, Director)William J. Rieflin(Executive Officer, Director)David V. Goeddel(Director)

BoardPeter Svennilson(Director)inMark Leschly(Director)David Schnell(Director)

Co-investorsProspect Venture Partners The Column Group

Novavax, Inc. (Alumni)

Nurix Therapeuticsnurixtx.com in 𝕏

Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)Mark Goldsmith(Director)

Co-investorsBain Capital Life Sciences EcoR1 Capital Sofinnova Ventures The Column Group

Obsidian Therapeutics, Inc.

Odyssey Therapeuticsodysseytx.com in 𝕏

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)

BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)

Co-investorsActivant Capital Balderton Capital Catalio Capital Management, LP Global BioAccess Fund GreatPoint Ventures Jeito Capital +6 more

OptiNoseoptinose.com

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.

BiotechHealthtechMedical DevicesYardley, US

Per Djupesland(Executive Officer, Director)Michele Janis(Executive Officer)Peter Miller(Executive Officer, Director)Terrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)

BoardKlaas De Boer(Director)

Co-investorsMVM Life Science Partners

Orchard Therapeuticsorchard-tx.com in 𝕏

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)Steven M. Altschuler(Director)John Curnutte(Director)

BoardBobby Gaspar(Scientific Founder)in

Co-investorsAlbionVC F-Prime Capital UCL Technology Fund Agent Capital Baillie Gifford ORI Capital +1 more

Peloton Therapeutics

Pharvarispharvaris.com in 𝕏

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBain Capital Life Sciences Kurma Partners venBio Partners

Phaxiam Therapeutics S A

Pinnacle Medicinespinnaclemedicines.com in

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

Chengzao Sun(Founder)Sandeep Somani(Founder)

Co-investorsQuan Capital RA Capital

Population Health Investment Co

Propeller Bio, LLC

Puma Biotechnology, Inc. (Alumni)

Quantum Siquantum-si.com in 𝕏

Quantum-Si develops benchtop instruments (Platinum and Platinum Pro) for single-molecule, single-amino-acid resolution protein sequencing, used to identify proteins, protein variants, and post-translational modifications.

BiotechHardwareMedical Devices

Co-investorsHighCape Capital YuanBio Venture Capital

RAPT Therapeutics

Co-investorsMedicxi

RayTheraraythera.com

RayThera develops small molecule therapies targeting unmet needs in immunology.

BiotechHealthtech

Co-investorsOrbiMed

Redesign Healthredesignhealth.com in

Redesign Health is a venture capital and applied technology platform that builds and invests in next-generation healthcare companies using AI-native strategies.

AI & Machine LearningDigital HealthHealthtech

Co-investorsCVS Health Ventures Declaration Partners Forerunner Ventures Mantis Capital RiverPark Ventures Samsung Next

Regulus Therapeutics

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Jan 2017

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.

BiotechHealthtechBoston, US

Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)inTodd Foley(Director)

Co-investorsHEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Pfizer Venture Investments OrbiMed Third Rock Ventures

Sangamo Therapeuticssangamo.com in 𝕏

Sangamo is a genomic medicine company using its proprietary zinc finger technology to develop gene therapies aimed at curing severe diseases, with a focus on neurology and rare disorders.

BiotechMedical Devices

Co-investorsCalifornia Technology Ventures Foothill Ventures Ridgeback Capital

Sestina Bio

Signant Healthsignanthealth.com in 𝕏

Signant Health provides eClinical technology and services for clinical trial data collection, including electronic data capture, patient and site data solutions, and scientific and operational support.

Digital HealthHealthtechSaaS

Co-investorsGenstar

Site by Goodlabgoodlab.media in

Good Lab is a brand and design agency serving early-stage, rapid-growth ventures in health, wellness, environmental sciences, and life sciences.

Creator EconomyMarketing Tech

John Montgomery(Founder)in

Slate Medicinesslatemedicines.com inFeb 2026

Slate Medicines is a clinical-stage biotechnology company.

BiotechMedical DevicesBoston, US

Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)Gregory Frank Oakes(Executive Officer)Gregory Oakes(Chief Executive Officer and Board Director)

BoardTim Lohoff(Director)Cindy Xiong(Director)

Co-investorsRA Capital

Sollis Health

SomaLogicsomalogic.com

SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.

BiotechDeep TechHealthtechBoulder, US

Larry Gold PhD(Founder)inCharles Lillis(Director)Youichi Yabuuchi(Director)Terry Randall(Director)Al Reynolds(Director)Daniel Muehl(Executive Officer)

Co-investorsKhosla Ventures Casdin Capital

Sotera Wireless

HealthtechSan Diego, US

Thomas Watlington(Executive Officer, Director)Kenneth Buechler(Director)Walter Lim(Director)Charles Sted(Director)Matthew Buten(Director)Bobby Kandaswamy(Director)

Co-investorsSanderling Ventures Intel Capital Qualcomm Ventures

Stepful, Inc.

Structure Therapeuticsstructuretx.com in 𝕏

Co-investorsF-Prime Capital Qiming Venture Partners

Tassotassoinc.com in 𝕏Dec 2019

Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.

Digital HealthHealthtechMedical DevicesSeattle, US

Ben Casavant(Co-Founder and Chief Executive Officer)Erwin Berthier(Co-Founder and Chief Technology Officer)Alan Levy(Director)

BoardElizabeth Hambrecht(Director)Paul Conley(Director)in

Co-investorsJ2 Ventures OMX Ventures RA Capital Techstars Venture Capital Investment Management Vertical Venture Partners

TenSixteen Bio

Tessera Therapeutics

The Medicines Company

Theseustheseus.us in

Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.

Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US

Ian Laffey(Founder)inSacha Lévy(Founder)in

Co-investorsY Combinator Antler First Round Capital Lux Capital

Third Arc Biothirdarcbio.com inJul 2024

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)

BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in

Co-investorsAndreessen Horowitz Vida Ventures abrdn plc Biotechnology Value Fund Hillhouse Investment Omega Funds +1 more

Thymemeetthyme.com inNov 2025 · $97MAcquired

Thyme has partnered with Altruist to create Hazel, an AI product for wealth management professionals.

AI & Machine LearningEnterprise SoftwareFintechSan Francisco, US

Daniel Lantz(Founder)inFernando San Martin(Founder)in

Co-investorsY Combinator AlleyCorp Concord Health Partners CVS Health Ventures Frist Cressey Ventures Humana +1 more

Thyme Carethymecare.com in 𝕏Sep 2025

Thyme Care develops software to enhance care coordination and outcomes for cancer patients.

Digital HealthHealthtechNashville, US

Robert Green(Executive Officer, Director)Robin Shah(Executive Officer, Director)inBobby Green(Founder)in

BoardBrian Belsky(Director)inElizabeth Canis(Director)inBrenton Fargnoli(Director)in

Co-investorsAlleyCorp Andreessen Horowitz Corewell Health Ventures CVS Health Ventures Echo Health Ventures Frist Cressey Ventures +4 more

Turning Point Therapeuticstptherapeutics.com

Co-investorsLAV Lilly Asia Ventures Nextech Invest Sv Tech Ventures, Inc.

Uniqureuniqure.com in 𝕏

uniQure is a gene therapy company developing treatments for Huntington's disease and other serious medical conditions.

BiotechHealthtech

Matthew Kapustain

Co-investorsAdvent Life Sciences HEALTHCARE ROYALTY PARTNERS

Velia

Venatorx Pharmaceuticals

Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.

Malvern, US

Co-investorsAMR Action Fund BioAdvance

Browse all 208 investments with full details →

▶8 more tracked companies

Verona Pharma Verve Therapeutics Vignette BioVitae PharmaceuticalsVoyager Therapeutics (Alumni)Xaira TherapeuticsXintheraZenefits

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 54

IPOs and acquisitions across the tracked portfolio

Portfolio news

latest coverage across their companies

Hims & Hers Health (HIMS) & Novo Nordisk A/S (NVO): Two Weight-Loss Pill Players Just Got Punished for Growing Fast - Insider Monkey

Hims & Hers · insidermonkey.com · Aug 21, 2026

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Adaptive Biotechnologies · barchart.com · Aug 21, 2026

Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM

Cullinan Therapeutics · marketbeat.com · Aug 21, 2026

H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com

Relay Therapeutics · investing.com · Aug 20, 2026

KB Element Raises 14 Billion Won in Series B Funding < Supply Chain < 기사본문 - The Elec Inc.

Element · thelec.net · Aug 20, 2026

Abcuro secures $66m to support clinical trial of ulviprubart for IBM

Abcuro · clinicaltrialsarena.com · Aug 19, 2026

Investigation launched into Arcus Biosciences o... | Pluang

Arcus Biosciences · pluang.com · Aug 19, 2026

CG Oncology stock hits all-time high of 79.5 USD By Investing.com

CG Oncology · investing.com · Aug 19, 2026

Frequently asked questions

How many investments has Foresite Capital made?: Foresite Capital has 215 tracked investments, 11 of which have exited via acquisition or IPO, including 5 dated in the last 24 months.
What stage does Foresite Capital invest at?: Foresite Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Foresite Capital focus on?: Foresite Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Foresite Capital located?: Foresite Capital is headquartered in West Hollywood, US.
Does Foresite Capital lead rounds?: Foresite Capital has led 5 of the 19 rounds where its role is on record.
Who does Foresite Capital co-invest with?: Foresite Capital most often shares deals with RA Capital, OrbiMed, ARCH Venture Partners, among 243 tracked co-investors.

From the blog

visit blog ↗

Foresite Capital has invested in healthcare innovations across diagnostics, urgent care delivery, and neuropsychiatric drug development, with a focus on companies addressing significant unmet patient needs through differentiated technologies and consumer-driven models. AI summary

Q&A with Foresight Diagnostics on their acquisition by NateraDec 2025Foresite Capital portfolio company Foresight Diagnostics was acquired by Natera; founders discuss leadership lessons from building and exiting the ctDNA diagnostics company.Sollis Health: Redefining Urgent and Emergency CareApr 2025Foresite led a $35M Series B in Sollis Health, a membership-based urgent and emergency care provider with 24/7 access and strong unit economics.Welcoming Seaport Therapeutics to Our PortfolioOct 2024Foresite invested in Seaport Therapeutics, a neuropsychiatric drug developer using a novel lymphatic-delivery platform for major depressive disorder treatments.

Media · Podcasts & interviews

featuring the team

Jim Tananbaum, Foresite Capital Founder on Healthcare & Life Sciences

Grace Gong · Jim Tananbaum

How AI Is Rewriting Drug Discovery and Biotech Investing | Jim Tananbaum of Foresite Capital

Nicholas Moran · Jim Tananbaum

Why Jim Tananbaum, Founder & CEO of Foresite Capital, is excited by the Element AVITI

Element Biosciences · Jim Tananbaum

Images

Co-investors · 29

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

$1M – $75M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 14

Aclaris Therapeutics Beam Therapeutics Compass Therapeutics Denali Therapeutics InsmedBicara TherapeuticsBlueprint Medicines Engrail Therapeutics Generation Bio Genomics Plc Orchard Therapeutics Verve Therapeutics Xaira TherapeuticsStructure Therapeutics

$3M – $10M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 13

Beam Therapeutics Denali Therapeutics GRAIL Kura Oncology Maze Therapeutics Parabilis Medicines Seaport Therapeutics Bit Bio Insitro Lyell Remix Therapeutics Verve Therapeutics Xaira Therapeutics

$50K – $250M

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 12

Alumis Alx Oncology Aura Biosciences Compass Therapeutics Parabilis Medicines Syndax Pharmaceuticals Akero Candid Therapeutics Lyell Pharvaris Verona Pharma Verve Therapeutics

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 9

Abcuro Ardelyx Avenzo Curisium Dermira Rhythm Pharmaceuticals Verona Pharma Xaira TherapeuticsHealthcare North America Growth Stage

$200K – $40M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 7

Beam Therapeutics Denali Therapeutics Maze Therapeutics Cerevance Dnanexus Insitro Verve Therapeutics

$250K – $50M

Venrock

Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.

Both backed · 7

10x GenomicsAcceleron Element Element Biosciences Inscripta ZenefitsVitae Pharmaceuticals

$500K – $10M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 6

Disc Medicine Intellia Therapeutics Akero Generation Bio Ikena Oncology, Inc.Remix Therapeutics

$500K – $1M

Aisling Capital

Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.

Both backed · 6

Aclaris TherapeuticsBicara TherapeuticsArcus Biosciences Ascendis Pharma Dermira Verona Pharma

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 5

Maze Therapeutics Insitro Third Arc Bio Thyme Care Zenefits

$500K – $50M

Flare Capital Partners

Flare Capital Partners is a healthcare technology-focused venture firm that partners with founders building companies to improve outcomes, lower costs, and reshape healthcare delivery.

Both backed · 4

CurisiumAetionHealthcare North America Growth StageHealthVerity

$1M – $10M

▶17 more co-investors

The Column Group Menlo Ventures 5AM Ventures Pontifax Venture Capital Westlake Village BioPartners First Round Capital Deerfield Management Company Sequoia Capital Bain Capital Ventures General Atlantic Wildcat Venture Partners Torch Capital Molten Ventures Northpond Ventures Maverick Capital Recode Ventures Civilization Ventures Management, Llc

Firms observed investing alongside Foresite Capital, from public investor directories. Shared companies are the overlap with Foresite Capital's recorded portfolio.

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

$5K – $50M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Pre-Seed Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States AI & Machine Learning Investors & VC Firms

Website & social

foresitecapital.com

/foresite-capital-management @foresitecapital

signal ↗crunchbase ↗Blog ↗

As published on the firm's website.

Contact

West Hollywood9200 Sunset Boulevard
Suite PH1
West Hollywood, CA 90069
United States

New York1330 Avenue of the Americas
35th Floor
New York, NY 10019
United States

Phone310 981 3630

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

Foresite Capital isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

FORESITE CAPITAL FUND VI LPvintage 2022 · 494 LPs · 506(b)$1.1BAUM

FORESITE CAPITAL VI-A, LLCvintage 2021 · 18 LPs · 506(b)$18MAUM

FORESITE CAPITAL FUND V, L.P.vintage 2019 · 406 LPs · 506(b)$753.9MAUM

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.vintage 2019 · 406 LPs · 506(b)$227.4MAUM

FORESITE CAPITAL FUND IV, LPJul 2026 · 178 LPs$860MAUM

FORESITE LABS FUND I, L.P.Jul 2026 · 97 LPs$130.8MAUM

FORESITE CAPITAL FUND III, LPJul 2026 · 163 LPs$110.7MAUM

FORESITE CAPITAL FUND II, LPJul 2026 · 139 LPs$10.8MAUM

FORESITE PUBLIC & CROSSOVER OPPORTUNITIES FUND I, L.P.Jul 2026

also operates 1 feeder

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.

Latest on 𝕏

Foresite Capital @foresitecapital

Today we announced Fund VI, which represents hard work from many members of our team. So grateful to our investors for their support. Read more in @FierceBiotech: @https://www.fiercebiotech.com/biotech/foresite-raises-900m-make-big-bets-one-best-biotech-investment-environments

Jun 12, 2024 · ♥ 7 · ⇄ 2

Foresite Capital @foresitecapital

Today we welcome @xaira_therapeutics to our portfolio, emerging from stealth with $1B in committed capital; jointly incubated by Arch Venture Partners / @rtnarch and @ForesiteLabs and led by Marc Tessier-Lavigne. Read more: https://t.co/Ge0Kfn0jS7

Apr 23, 2024 · ♥ 8 · ⇄ 2

Foresite Capital @foresitecapital

We welcome Hadi Tabbaa, our new managing director of investor relations and business development! With 2+ decades of experience, Hadi is set to strengthen our investor partnerships and bring invaluable expertise to Foresite Capital. Welcome aboard, Hadi! https://t.co/dDmXFx8lPf https://t.co/BHYXeHBvsP

Sep 28, 2023 · ♥ 4 · ⇄ 1